Notice of in-court restructuring proceedings of Orphazyme A/S
18 mars 2022 06h40 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 11/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 18, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Commencement of in-court restructuring of Orphazyme A/S
10 mars 2022 16h05 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 10/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Will institute a reduction of approximately 50% of current work forceIntends to...
Updated Financial Calender for 2022
03 mars 2022 03h35 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 09/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 3, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Anders Vadsholt takes over as CEO of Orphazyme
28 févr. 2022 02h25 HE
|
ORPHAZYME A/S
Company announcementNo. 08/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 28, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Orphazyme announces update on regulatory review of arimoclomol in the European Union
23 févr. 2022 16h05 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US))...
Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program
18 févr. 2022 16h01 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 06/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 18, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a...
Resolutions passed at the Extraordinary General Meeting
15 févr. 2022 12h15 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 05/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 15, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the...
Amendment of proposals put forward at the Extraordinary General Meeting
14 févr. 2022 16h01 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 04/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 14, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the...
Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States
11 févr. 2022 01h50 HE
|
ORPHAZYME A/S
Orphazyme A/SInvestor newsNo. 02/2022www.orphazyme.comCompany Registration No. 32266355 Orphazyme has made progress towards resubmission of the NDA for arimoclomol to the FDA and plans to request a...
Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™
07 févr. 2022 06h22 HE
|
ORPHAZYME A/S
Orphazyme A/SInvestor NewsNo. 01/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 7, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...